# Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Canonical URL: https://biopharmsignal.com/news/IMMX/immix-biopharma-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis-trial-nexicart-2
Ticker: IMMX
Company: Immix Biopharma
Source: Immix Biopharma
Published: 2024-08-28 09:32 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p> </p> <ul><li>New Sites Expand Opportunities for Patient Access and Enrollment </li><li>Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health </li><li>Lead site

## Article Body
New Sites Expand Opportunities for Patient Access and Enrollment

Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health

Lead site Memorial Sloan Kettering Cancer Center (MSKCC)

Data from ex-U.S. clinical trial reported at ASGCT 2024 showed a 92% overall response rate

LOS...
## Recent Company News
- 2026-05-22 17:15 EST — [Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-closing-of-150-million-underwritten-offering-of-common-stock) — Source: Immix Biopharma
- 2026-05-21 06:30 EST — [Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-pricing-of-150-million-underwritten-offering-of-common-stock) — Source: Immix Biopharma
- 2026-05-21 06:00 EST — [Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-95-complete-response-rate-in-interim-update-from-relapsed-refractory-al-amyloidosis-clinical-trial-nexicart-2) — Source: Immix Biopharma
- 2026-04-09 08:45 EST — [Immix Biopharma to Participate in the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/IMMX/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference) — Source: Immix Biopharma
- 2026-03-30 08:45 EST — [Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones](https://biopharmsignal.com/news/IMMX/immix-biopharma-announces-enrollment-completion-of-bla-enabling-relapsed-refractory-al-amyloidosis-trial-nexicart-2-and-upcoming-milestones) — Source: Immix Biopharma
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)